Watch Ticker

Zymeworks Inc.

Go to Zymeworks Inc. Website

$12.60

0.03 (0.24%)
Live
Previous Close

$12.57

Day Range

$12.36 - $12.72

Previous Day Range

$12.2612 - $12.7

Market Cap

$940.8 million USD

Day Vol.

290909

Previous Day Vol.

637973

Currency

USD

Primary Exchange

Nasdaq

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development...

Community
  • 0 posts discussing
0

Watchers

0

Visitors

Recent News

Zymeworks, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 7, 2025, and participate in upcoming investor conferences. The company has received regulatory approvals for zanidatamab, a HER2-targeted bispecific antibody for biliary tract cancer treatment.

Related tickers: ZYME, ONC, JAZZ.

Read Full Article

Zymeworks' zanidatamab, a dual HER2-targeted bispecific antibody, has received conditional approval from China's NMPA for the treatment of previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This milestone affirms zanidatamab's clinical potential and Zymeworks' commitment to developing innovative therapies for difficult-to-treat diseases.

Related tickers: ZYME, BGNE, ONC, JAZZ.

Read Full Article
Trending Tickers

Please sign in to view